James Chelnis, MD, FACS, is an ophthalmic plastic and reconstructive surgeon at Manhattan Face & Eye. At the 2025 American ...

The Phase 3 ADAPT SERON study met its primary endpoint (p-value=0.0068), demonstrating that AChR-Ab seronegative gMG patients treated with VYVGART achieved a statistically significant improvement in ...

Phase 2 clinical trial underway with first patient dosed in October to support a clear path to Phase 3 based on previous ...

Basel, October 29, 2025 – Novartis today presented new ianalumab data in Sjögren’s disease, the second most prevalent rheumatic autoimmune disease 2, at a late-breaker presentation during the American ...

Phase 3 Trial Design: The FDA agreed with Adagene’s proposed standard-of-care (SOC) control arm for the Phase 3 clinical trial and confirmed that a muzastotug monotherapy arm was also not required.

Rosnilimab acts as an agonist to stimulate PD-1, killing those cells with high PD-1 expression and pushing others into an ...

Findings highlight opportunity for shared decision-making to improve treatment planning, with more than 90% of patients currently on injectables willing to switch ...

The poster will be made available on the Presentations & Research page of Unicycive’s website following the poster ...

On September 9, 2025, President Trump issued a Presidential Memorandum directing the Secretary of Health and Human Services ...

NEPTUNUS-1 and NEPTUNUS-2 achieved primary objective of reduced disease activity and provided clinically meaningful benefit1 Data showed consistent improvements across secondary outcome measures, and ...

A recent legislative hearing left people involved in the state’s medical marijuana businesses paranoid, and it wasn’t because ...